BioLineRx (BLRX) Tops Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BioLineRx Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 18, 2021 7:00 AM EST- Positive results from pharmacoeconomic cost effectiveness study of Motixafortide in stem cell mobilization support its use as standard of care in combination with G-CSF -
- Pre-NDA meeting with FDA set for mid-December; NDA submission planned for H1 2022 -
- Cash and cash equivalents at September 30, 2021 of $62.2 million -
- Management to hold conference call today, November 18, at 10:00 am EST -
TEL AVIV, Israel, Nov. 18, 2021 /PRNewswire/ --Â BioLineRx Ltd. (NASDAQ: BLRX) (TASE:... More
